Cargando…

Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis

Abatacept (ABA) is an immunosuppressant indicated for treatment of rheumatoid arthritis (RA). Effectiveness might be influenced by clinical RA variants and single-nucleotide polymorphisms (SNPs) in genes encoding protein FCGR2A (His131Arg) and FCGR3A (Phe158Val) involved in pharmacokinetics of ABA....

Descripción completa

Detalles Bibliográficos
Autores principales: Márquez Pete, Noelia, Maldonado Montoro, María del Mar, Pérez Ramírez, Cristina, Martínez Martínez, Fernando, Martínez de la Plata, Juan Enrique, Daddaoua, Abdelali, Jiménez Morales, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233911/
https://www.ncbi.nlm.nih.gov/pubmed/34207385
http://dx.doi.org/10.3390/jpm11060573
_version_ 1783713960253456384
author Márquez Pete, Noelia
Maldonado Montoro, María del Mar
Pérez Ramírez, Cristina
Martínez Martínez, Fernando
Martínez de la Plata, Juan Enrique
Daddaoua, Abdelali
Jiménez Morales, Alberto
author_facet Márquez Pete, Noelia
Maldonado Montoro, María del Mar
Pérez Ramírez, Cristina
Martínez Martínez, Fernando
Martínez de la Plata, Juan Enrique
Daddaoua, Abdelali
Jiménez Morales, Alberto
author_sort Márquez Pete, Noelia
collection PubMed
description Abatacept (ABA) is an immunosuppressant indicated for treatment of rheumatoid arthritis (RA). Effectiveness might be influenced by clinical RA variants and single-nucleotide polymorphisms (SNPs) in genes encoding protein FCGR2A (His131Arg) and FCGR3A (Phe158Val) involved in pharmacokinetics of ABA. An observational cohort study was conducted in 120 RA Caucasian patients treated with ABA for 6 and 12 months. Patients with the FCGR2A rs1801274-AA genotype (FCGR2A-p.131His) showed a better EULAR response (OR = 2.43; 95% CI = 1.01–5.92) at 12 months and low disease activity (LDA) at 6 months (OR = 3.16; 95% CI = 1.19–8.66) and 12 months (OR = 6.62; 95% CI = 1.25–46.89) of treatment with ABA. A tendency was observed towards an association between the FCGR3A rs396991-A allele (FCGR3A-p.158Phe) and better therapeutic response to ABA after 12 months of treatment (p = 0.078). Moreover, we found a significant association between the low-affinity FCGR2A/FCGR3A haplotypes variable and LDA after 12 months of ABA treatment (OR = 1.59; 95% CI = 1.01–2.58). The clinical variables associated with better response to ABA were lower age at starting ABA (OR = 1.06; 95% CI = 1.02–1.11) and greater duration of ABA treatment (OR = 1.02; 95% CI = 1.01–1.04), lower duration of previous biological therapies (OR = 0.99; 95% CI = 0.98–0.99), non-administration of concomitant disease-modifying antirheumatic drugs (DMARDs) (OR = 24.53; 95% CI = 3.46–523.80), non-use of concomitant glucocorticoids (OR = 0.12; 95% CI = 0.02–0.47), monotherapy (OR = 19.22; 95% CI = 2.05–343.00), lower initial patient’s visual analogue scale (PVAS) value (OR = 0.95; 95% CI = 0.92–0.97), and lower baseline ESR (OR = 0.92; 95% CI = 0.87–0.97). This study showed that high-affinity FCGR2A-p.131His variant, low-affinity FCGR3A-p.158Phe variant, and combined use of FCGR2A/FCGR3A genetic variations could affect ABA effectiveness. Further studies will be required to confirm these results.
format Online
Article
Text
id pubmed-8233911
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82339112021-06-27 Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis Márquez Pete, Noelia Maldonado Montoro, María del Mar Pérez Ramírez, Cristina Martínez Martínez, Fernando Martínez de la Plata, Juan Enrique Daddaoua, Abdelali Jiménez Morales, Alberto J Pers Med Article Abatacept (ABA) is an immunosuppressant indicated for treatment of rheumatoid arthritis (RA). Effectiveness might be influenced by clinical RA variants and single-nucleotide polymorphisms (SNPs) in genes encoding protein FCGR2A (His131Arg) and FCGR3A (Phe158Val) involved in pharmacokinetics of ABA. An observational cohort study was conducted in 120 RA Caucasian patients treated with ABA for 6 and 12 months. Patients with the FCGR2A rs1801274-AA genotype (FCGR2A-p.131His) showed a better EULAR response (OR = 2.43; 95% CI = 1.01–5.92) at 12 months and low disease activity (LDA) at 6 months (OR = 3.16; 95% CI = 1.19–8.66) and 12 months (OR = 6.62; 95% CI = 1.25–46.89) of treatment with ABA. A tendency was observed towards an association between the FCGR3A rs396991-A allele (FCGR3A-p.158Phe) and better therapeutic response to ABA after 12 months of treatment (p = 0.078). Moreover, we found a significant association between the low-affinity FCGR2A/FCGR3A haplotypes variable and LDA after 12 months of ABA treatment (OR = 1.59; 95% CI = 1.01–2.58). The clinical variables associated with better response to ABA were lower age at starting ABA (OR = 1.06; 95% CI = 1.02–1.11) and greater duration of ABA treatment (OR = 1.02; 95% CI = 1.01–1.04), lower duration of previous biological therapies (OR = 0.99; 95% CI = 0.98–0.99), non-administration of concomitant disease-modifying antirheumatic drugs (DMARDs) (OR = 24.53; 95% CI = 3.46–523.80), non-use of concomitant glucocorticoids (OR = 0.12; 95% CI = 0.02–0.47), monotherapy (OR = 19.22; 95% CI = 2.05–343.00), lower initial patient’s visual analogue scale (PVAS) value (OR = 0.95; 95% CI = 0.92–0.97), and lower baseline ESR (OR = 0.92; 95% CI = 0.87–0.97). This study showed that high-affinity FCGR2A-p.131His variant, low-affinity FCGR3A-p.158Phe variant, and combined use of FCGR2A/FCGR3A genetic variations could affect ABA effectiveness. Further studies will be required to confirm these results. MDPI 2021-06-18 /pmc/articles/PMC8233911/ /pubmed/34207385 http://dx.doi.org/10.3390/jpm11060573 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Márquez Pete, Noelia
Maldonado Montoro, María del Mar
Pérez Ramírez, Cristina
Martínez Martínez, Fernando
Martínez de la Plata, Juan Enrique
Daddaoua, Abdelali
Jiménez Morales, Alberto
Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis
title Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis
title_full Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis
title_fullStr Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis
title_full_unstemmed Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis
title_short Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis
title_sort influence of the fcgr2a rs1801274 and fcgr3a rs396991 polymorphisms on response to abatacept in patients with rheumatoid arthritis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233911/
https://www.ncbi.nlm.nih.gov/pubmed/34207385
http://dx.doi.org/10.3390/jpm11060573
work_keys_str_mv AT marquezpetenoelia influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis
AT maldonadomontoromariadelmar influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis
AT perezramirezcristina influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis
AT martinezmartinezfernando influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis
AT martinezdelaplatajuanenrique influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis
AT daddaouaabdelali influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis
AT jimenezmoralesalberto influenceofthefcgr2ars1801274andfcgr3ars396991polymorphismsonresponsetoabataceptinpatientswithrheumatoidarthritis